Irinotecan
Germ Cell Tumor
New York Medical CollegeSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Nabil Adra | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Hoffmann-La Roche | Phase 3 | BB |
Carboplatin Hoffmann-La Roche | Phase 3 | BB |
Inno-206 Children's National Research Institute | Phase 2 | B |
BLEOMYCIN Children's Oncology Group | Phase 3 | B |
View all 24 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →